Literature DB >> 7162459

Drug control of Ara-C-resistant tumor cells.

F M Schabel, H E Skipper, M W Trader, R W Brockman, W R Laster, T H Corbett, D P Griswold.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 7162459     DOI： 10.1002/mpo.2950100713

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN： 0098-1532


× No keyword cloud information.
  5 in total

1.  Pharmacodynamic and DNA methylation studies of high-dose 1-beta-D-arabinofuranosyl cytosine before and after in vivo 5-azacytidine treatment in pediatric patients with refractory acute lymphocytic leukemia.

Authors:  V I Avramis; R A Mecum; J Nyce; D A Steele; J S Holcenberg
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Cellular metabolism of 5,6-dihydro-5-azacytidine and its incorporation into DNA and RNA of human lymphoid cells CEM/O and CEM/dCk(-).

Authors:  V I Avramis; W C Powell; R A Mecum
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 3.  Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.

Authors:  D Faulds; J A Balfour; P Chrisp; H D Langtry
Journal:  Drugs       Date:  1991-03       Impact factor: 9.546

4.  Biochemical pharmacology of 5,6-dihydro-5-azacytidine (DHAC) and DNA hypomethylation in tumor (L1210)-bearing mice.

Authors:  W C Powell; V I Avramis
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

5.  Cellular metabolism of 1-beta-D-arabinofuranosyl-5-azacytosine and incorporation into DNA and RNA of human lymphoid CEM/0 and CEM/dCk(-) cells.

Authors:  V I Avramis; W C Powell; R A Mecum
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.